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The abnormal accumulation of the microtubule-binding protein tau is associated with a number of neurode-
generative conditions, and correlates with cognitive decline in Alzheimer’s disease. The ubiquitin ligase car-
boxy terminus of Hsp70-interacting protein (CHIP) and the molecular chaperone Hsp90 are implicated in
protein triage decisions involving tau, and have consequently been targeted for therapeutic approaches
aimed at decreasing tau burden. Here, we present evidence that CHIP binds, ubiquitinates and regulates ex-
pression of histone deacetylase 6 (HDAC6). As the deacetylase for Hsp90, HDAC6 modulates Hsp90 function
and determines the favorability of refolding versus degradation of Hsp90 client proteins. Moreover, we dem-
onstrate that HDAC6 levels positively correlate with tau burden, while a decrease in HDAC6 activity or expres-
sion promotes tau clearance. Consistent with previous research on Hsp90 clients in cancer, we provide
evidence that a loss of HDAC6 activity augments the efﬁcacy of an Hsp90 inhibitor and drives client degrad-
ation, in this case tau. Therefore, our current ﬁndings not only identify HDAC6 as a critical factor for the regu-
lation of tau levels, but also indicate that a multi-faceted treatment approach could more effectively arrest tau
accumulation in disease.
INTRODUCTION
The microtubule-binding protein tau is central to the regula-
tion of axonal outgrowth and cellular morphology, as well
as neuronal transport (1–3). In a number of neurodegenerative
diseases classiﬁed as tauopathies, which include frontotem-
poral dementia with parkinsonism associated with chromo-
some 17, progressive supranuclear palsy, corticobasal
degeneration, and Alzheimer’s disease (AD), tau becomes
hyperphosphorylated and aggregates into ﬁlaments, thus
losing the ability to bind and stabilize microtubules (4,5).
These tau ﬁlaments continue to aggregate and form increasing-
ly insoluble deposits referred to as neuroﬁbrillary tangles. Al-
though AD is the most common tauopathy and most frequent
cause of dementia, the available treatment options only treat
the symptoms of AD, and do nothing to alleviate the under-
lying pathology. Therefore, understanding the mechanism by
which hyperphosphorylated tau is cleared by neurons, and
developing therapeutics to eliminate these toxic species are
of considerable interest.
Previously, the ubiquitin ligase carboxy terminus of Hsp70-
interacting protein (CHIP) and the molecular chaperone Hsp90
have been shown to play pivotal roles in protein triage deci-
sions involving tau (6–9). CHIP has a unique binding afﬁnity
for abnormally phosphorylated tau and is required for tau ubiqui-
tination and targeting to proteasomes for degradation (6–8). For
its part, Hsp90, a ubiquitous, constitutively expressed protein
that constitutes 1–2% of total cellular protein in eukaryotic
cells (10,11), functions to maintain its client proteins in a
properly folded state and thereby suppresses their aggregation
(10). During conditions of stress, this dual function of Hsp90
helps to repair the pool of damaged client proteins, thus
serving to reestablish a state of cellular equilibrium (12).
Over 100 proteins have been reported to be clients of Hsp90
(12,13), including protein kinases, transcriptional regulators,
and steroid receptors (12). Of particular relevance to the
current report, tau is also an Hsp90 client (9,14).
Following binding of Hsp90, client proteins either enter a
refolding pathway, leading to a functional, properly folded
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ubiquitin-proteasome system (15). The speciﬁc components
of the Hsp90 complex ultimately determine whether client
refolding or degradation occurs (16). Nucleotide binding to
Hsp90 is proposed to alter its conformation and deﬁne the
subset of chaperones with which it interacts (16). In the ADP-
bound conformation, Hsp90 associates with client-bound
Hsp70/Hsp40 complexes. At this point, the complex may
recruit ubiquitin ligases, such as CHIP, to direct the client to
proteasomes for degradation. The replacement of ADP with
ATP alters Hsp90 conformation, releasing Hsp70/Hsp40 and
allowing the recruitment of other cochaperones, including
p23. This complex folds and stabilizes the client now bound
by Hsp90. Notably, the acetylation state of Hsp90 modulates
Hsp90 function (17–20); speciﬁcally, Hsp90 hyperacetylation
decreases the afﬁnity of Hsp90 for ATP and oncogenic client
proteins, and causes the dissociation of p23 from the Hsp90
complex, leading to an impairment in chaperone function
and promoting client degradation (18,21).
Of importance, inhibition or depletion of histone deacety-
lase 6 (HDAC6) promotes the hyperacetylation of Hsp90,
thus augmenting the polyubiquitination and subsequent deg-
radation of Hsp90 client proteins (17–20). Hyperacetylation
of Hsp90 due to HDAC6 depletion also leads to an increased
binding afﬁnity of Hsp90 for Hsp90 inhibitors (21,22). Hsp90
inhibitors disrupt Hsp90 chaperone function such that client
proteins are instead degraded (reviewed in 23). That cotreat-
ment of leukemia cells with HDAC6 and Hsp90 inhibitors
synergistically promotes the degradation of Hsp90 client pro-
teins suggests that the hyperacetylation of Hsp90 by HDAC6
augments the pro-degradation effects of Hsp90 inhibitors
(21,24). Therefore, it is possible that alterations in Hsp90
acetylation, either through differences in expression or activity
of the deacetylase HDAC6, determine the sensitivity of the
Hsp90 chaperone complex to chemical modulation, ultimately
deciding the fate of Hsp90 client proteins, such as tau. Here,
we provide evidence that CHIP interacts with and regulates
the half-life of HDAC6 in cells and in mice. In addition, we
demonstrate that increased levels of HDAC6 lead to an accu-
mulation of tau, while decreased HDAC6 levels or activity
promotes tau clearance and increases the efﬁcacy of Hsp90
inhibitors. Therefore, we hypothesize that CHIP, by regulating
HDAC6 levels, inﬂuences protein triage decisions by modulat-
ing the refolding and degradation activities of Hsp90.
RESULTS
CHIP interacts with and ubiquitinates HDAC6
To investigate whether HDAC6 is a substrate for CHIP,
co-immunoprecipitation experiments were conducted in the
presence and absence of proteasome inhibition (MG132) to
slow the degradation of ubiquitinated proteins. HEK293T
cells were transfected to express HA-tagged ubiquitin
(HA-ubiquitin) and myc-HDAC6, along with either CHIP or
GFP, and HDAC6 was then immunoprecipitated from cell
lysates using an anti-myc antibody. As shown in Figure 1A,
CHIP co-immunoprecipitated with HDAC6, and multiple
HDAC6- and HA-ubiquitin-positive high molecular weight
species were observed in CHIP-overexpressing cells, likely
representing ubiquitinated HDAC6.
To further characterize the interaction between CHIP and
HDAC6, we sought to determine whether CHIP binds
HDAC6 directly or whether chaperones Hsp70/Hsp90 serve to
bridge the two proteins. Thus, HeLa cells were co-transfected
to overexpress HDAC6 and either wild-type (WT) myc-CHIP,
myc-CHIP(K30A) or myc-CHIP(H260Q). The K30A mutation
prevents CHIP from docking with chaperones Hsp70/Hsp90,
while the H260Q mutation, present within the U-box of CHIP,
obliterates ubiquitin ligase activity (25). Upon immunoprecipi-
tationforHDAC6,bothWTmyc-CHIPandmyc-CHIP(H260Q)
were found to bind HDAC6 (Fig. 1B). In contrast, little myc-
CHIP(K30A) co-immunoprecipitated with HDAC6, suggesting
that either Hsp70 or Hsp90 is required for the interaction
between CHIP and HDAC6.
Since CHIP plays a role in promoting the ubiquitination and
proteasomal degradation of several proteins, it was next eval-
uated whether loss of CHIP inﬂuences HDAC6 levels. To this
end, HeLa cells were transfected with either siCON or siCHIP
for 48 h, and subsequently transfected with mycHDAC6 for an
additional 24 h. Cells were then treated with cycloheximide
(CHX) to inhibit new protein translation, and cell lysates
were collected at various time points thereafter. Interestingly,
loss of CHIP increased steady-state levels of mycHDAC6 by
2.2-fold in cultured cells, and also prolonged its half-life
(Fig. 2A–C).
To investigate the impact of decreased CHIP levels in vivo,
brain homogenates from CHIP
2/2 and CHIP
+/+ mice were
prepared. In agreement with previous reports, loss of CHIP
led to an increase in PHF1-immunopositive tau levels
(Fig. 2D) (8). In addition, a signiﬁcant increase in HDAC6
levels was observed in CHIP
2/2 mice (Fig. 2D and E). Col-
lectively, these results indicate that HDAC6 is a substrate of
CHIP, and that the loss of CHIP impacts HDAC6 turnover
and leads to increased levels of HDAC6 in vitro and in vivo.
Overexpression of HDAC6 promotes tau accumulation
Given that the loss of CHIP is associated with an increase in
both HDAC6 and tau levels (Fig. 2), and that HDAC6 levels
are increased in AD (26), the effect of HDAC6 overexpression
on tau accumulation was evaluated by transfecting HeLa cells
to co-express tau with the pathogenic P301L mutation with
either GFP or HDAC6. Surprisingly, the co-expression of
P301L-tau with HDAC6 resulted in a dramatic upregulation
of tau levels, as detected using both PHF1 (pS396/S404) and
E1 (human tau speciﬁc) antibodies (Fig. 3A–D). As the over-
expression of HDAC6 led to a more signiﬁcant increase in
PHF1-tau than total human E1 tau (Fig. 3A–D), HDAC6 over-
expression may preferentially increase the accumulation of
pathologically phosphorylated tau species. To verify whether
HDAC6 overexpression speciﬁcally affects tau levels, cells
were transfected to coexpress HDAC6 and either GFP or
a-synuclein. No changes in GFP or a-synuclein expression
were observed in the presence of HDAC6 (Supplementary
Material, Fig. S1).
HDAC6-mediated tau accumulation may depend on the
deacetylase activity of HDAC6. Alternatively, given that
HDAC6 contains a ubiquitin-binding domain and has been
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targeting them to the aggresome, it is possible that HDAC6
directly binds and sequesters tau, thereby preventing tau deg-
radation. Thus, to determine whether the deacetylase activity
of HDAC6 is required to promote tau accumulation, a catalyt-
ically inactive mutant (H216A/H611A) of HDAC6 was gener-
ated and cells were transfected to express either this mutant or
WT HDAC6. As shown in Figure 3E–G, loss of deacetylase
activity prevented HDAC6 from promoting tau
accumulation, indicating that the catalytic activity of
HDAC6 is required for this effect. These results, in
combination with previous reports demonstrating that
HDAC6 regulates the acetylation state of Hsp90 (18,20–22),
suggest that HDAC6 overexpression increases the afﬁnity of
the Hsp90 chaperone complex for pathological tau species
by decreasing Hsp90 acetylation, thereby blocking tau degrad-
ation.
HDAC6 deﬁciency promotes tau degradation
We and others have shown that inhibitors of Hsp90 enhance
the degradation of mutated or hyperphosphorylated tau in
Figure 1. CHIP interacts with and ubiquitinates HDAC6 in vitro.( A) HEK293T cells were transfected with either GFP or CHIP in the presence of mycHDAC6
and HA-ubiquitin, and treated with the proteasome inhibitor, MG132, for 24 h. An anti-myc antibody was used to immunoprecipitate mycHDAC6 from cell
lysates, and samples were analyzed by western blot. (B) HEK293T cells were transfected with untagged HDAC6 or vector, and either GFP, myc-CHIP,
mycCHIP (K30A mutant) or mycCHIP (H260Q mutant). An HDAC6 antibody was used for immunoprecipitation, and cell lysates and immunoprecipitates
were probed for anti-myc.
Figure 2. Loss of CHIP prolongs the half-life of HDAC6 in vitro and increases HDAC6 levels in vivo.( A) HeLa cells transfected with mycHDAC6 were treated
with non-targeting siRNA (siCON) or siCHIP to knock-down endogenous CHIP for 48 h. Cells were then exposed to cycloheximide (CHX; 0.1 mg/ml) for 4, 8 or
12 h to inhibit the continued translation of mycHDAC6, and mycHDAC6 levels were examined by western blot using an anti-myc antibody. (B) Steady-state
levels (0 h CHX) of mycHDAC6 were signiﬁcantly higher in cultures treated with siCHIP compared with siCON-treated cultures (P , 0.005, t-test, n ¼ 3). (C)
The rate of degradation of mycHDAC6 post-CHX treatment in siCON- or siCHIP-treated cultures was compared by normalizing values at each time point to
their respective levels at 0 h CHX treatment. There was a signiﬁcant difference in the rate of degradation between siCON- and siCHIP-treated samples as
assessed by two-way ANOVA (effect of siCHIP F ¼ 388.3; P , 0.0001; effect of CHX treatment F ¼ 72.39; P , 0.0001; interaction F ¼ 10.71; P ¼
0.0004). Estimated half-life was the following: siCON, 4.7 h; siCHIP, 7.9 h. (D) HDAC6 and phosphorylated tau levels were examined in brain homogenates
from CHIP
+/+ and CHIP
2/2 mice using anti-HDAC6 and PHF1 antibody, respectively. Loss of CHIP leads to increased HDAC6 levels and anti-PHF1 immu-
noreactive phospho-tau in mice. (E) HDAC6 levels were signiﬁcantly higher in CHIP
2/2 compared with CHIP
+/+ brain homogenates (t ¼ 3; P , 0.05, n ¼ 4).
All data are presented as mean+SEM. ∗∗∗P , 0.001 ∗P , 0.05.
2938 Human Molecular Genetics, 2012, Vol. 21, No. 13vitro and in vivo, an effect that is dependent upon the presence
of CHIP (9,14,27). More speciﬁcally, our work reveals that
Hsp90 inhibition does not simply facilitate the proteasomal
degradation of tau, but selectively targets aberrantly phos-
phorylated tau, indicating that the surveillance mechanism of
the chaperone network is a highly sensitive and controlled
system (9,14,27,28). Since loss of HDAC6 activity has been
shown to increase the afﬁnity of Hsp90 for Hsp90 inhibitors,
such as 17AAG, as well as enhance 17AAG-mediated degrad-
ation of Hsp90 client proteins (21,22), we sought to evaluate
whether HDAC6 depletion would likewise enhance the deg-
radation of tau induced by Hsp90 inhibition. HeLa cells
were treated with siCON or siHDAC6, and then exposed to
17AAG. To conﬁrm efﬁcient Hsp90 inhibition, Hsp70 induc-
tion, a consequence of Hsp90 inhibition (15,29), was also
monitored (Fig. 4A and C). In contrast to HDAC6 overexpres-
sion, HDAC6 knockdown resulted in a decrease in P301L tau
levels compared with tau levels in siCON-treated cells, as
assessed using the PHF1 antibody (Fig. 4A and B, compare
vehicle-treated samples). In addition, treatment with 17AAG
led to a dose-dependent decrease in tau levels, which was
enhanced in cells treated with siHDAC6 (Fig. 4A and B). In
a similar fashion, enhanced tau clearance was observed upon
HDAC6 inhibition. Speciﬁcally, treatment with M344, an
HDAC6 inhibitor (30), led to a signiﬁcant decrease in tau
levels, and also augmented the ability of 17AAG to promote
tau degradation (Fig. 4C and D). As expected, the half-life
of tau is decreased in cells treated with M344, an effect that
is reversed in the presence of a proteasome inhibitor
(Fig. 4E and F). Taken together, these results suggest that
HDAC6 deﬁciency enhances tau degradation induced by
Hsp90 inhibitors, which is consistent with previous reports
showing that HDAC6 deﬁciency leads to an increased acetyl-
ation of Hsp90, thereby increasing the sensitivity of Hsp90 for
Hsp90 inhibitors (21,22).
HDAC6 deﬁciency modulates the expression
of the cochaperone p23
The cochaperone p23 locks Hsp90 in a conformational state
that has a high afﬁnity for client proteins (31). Hsp90 com-
plexes that contain p23 promote the folding and stabilization
of clients, rather than their degradation. Rao et al. demon-
strated that HDAC6 deﬁciency leads to a decreased interaction
between Hsp90 and p23 (21). In addition, we have reported
that the loss of p23 expression signiﬁcantly decreases tau
levels (9). Intriguingly, a signiﬁcant decrease in p23 was
detected upon both HDAC6 knockdown (Fig. 5A and B) and
HDAC6 inhibition with M344 (Fig. 5C and D), demonstrating
that the loss of HDAC6 function is associated with decreased
levels of p23. Given that decreased HDAC6 activity has been
shown to decrease the interaction between Hsp90 and p23
(21), the current results suggest that HDAC6 deﬁciency pro-
motes client degradation through the increased formation of
Hsp90 chaperone complexes that lack p23, which are charac-
terized by a very low afﬁnity for client proteins, such as tau.
Figure 3. Overexpression of HDAC6 promotes the accumulation of tau in vitro.( A) HeLa cells were transfected with GFP, P301L-V5 or HDAC6 expression
constructs for 48 h. Levels of phosphorylated and total tau present in cell lysates were then examined by immunoblotting with PHF1 and E1 antibodies, respect-
ively. HDAC6 overexpression was conﬁrmed by probing for HDAC6. (B) Analysis of PHF1-positive tau levels by student’s t-test veriﬁed that there was a sig-
niﬁcant increase in cells overexpressing HDAC6 (t ¼ 14.5; P , 0.0001). (C) Quantiﬁcation of E1 immunoreactivity normalized to GAPDH also revealed a
signiﬁcant increase in cells overexpressing HDAC6 (t ¼ 11.04; P ¼ 0.0004). (D) The ratio of PHF1-positive tau to E1-positive tau was signiﬁcantly increased
upon overexpression of HDAC6 (t ¼ 5.9; P ¼ 0.004), indicating that PHF1-tau is speciﬁcally increased in cells overexpressing HDAC6. (E) HeLa cells were
cotransfected with P301L-V5 and either GFP, mycHDAC6 or a catalytically inactive mycHDAC6 construct (H216/611A mutant). Cell lysates were immuno-
blotted for PHF1-tau, myc or actin to control for protein loading. (F) PHF1-tau levels were quantiﬁed and normalized to actin, and analyzed by one-way
ANOVA. Overexpression of mycHDAC6 caused a signiﬁcant increase in PHF1-tau levels (P , 0.001), but there was no effect of the catalytically inactive
mycHDAC6 mutant on PHF1-tau (P . 0.05). (G) Anti-myc levels were assessed and normalized to actin, verifying that both mycHDAC6 and the catalytically
inactive mutant were expressed at similar levels. All data are presented as mean+SEM (n ¼ 3). ∗∗∗P , 0.0001, ∗∗P , 0.001, ∗P , 0.01.
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neuronal cultures
To evaluate the signiﬁcance of these ﬁndings to neurodegen-
erative diseases characterized by the accumulation of tau in
neurons of the brain, the impact of HDAC6 inhibition on tau
levels was examined in primary neuronal cultures. Consistent
with the results above, a signiﬁcant decrease in PHF1-positive
tau levels was observed in neurons treated with M344 (Fig. 6A
and B). Treatment with M344 also led to an increase in the
acetylation of tubulin, conﬁrming that M344 did in fact
inhibit the deacetylase activity of HDAC6 (Fig. 6C). A signiﬁ-
cant decrease in p23 levels was also seen upon exposure to
M344 (Fig. 6D), suggesting that M344 drives the formation
of Hsp90 chaperone complexes favoring degradation, which
is sufﬁcient to promote tau clearance in neurons. In addition,
consistent with reports demonstrating that the loss of
HDAC6 activity increases the afﬁnity of Hsp90 for Hsp90
inhibitors (21,22), we observed an enhanced induction of the
inducible Hsp70 isoform in response to 17AAG in the pres-
ence of M344 (Fig. 6E and F). Given that the increased induc-
tion of inducible Hsp70 is observed at both the RNA and
protein levels, this indicates the upregulation is due to
increased HSF1-mediated gene transcription, and not due to
an altered half-life of Hsp70.
Figure 4. HDAC6 deﬁciency or inhibition decreases tau levels, and functions synergistically with Hsp90 inhibition to promote the degradation of tau. (A) HeLa
cells were transfected with siCON or siHDAC6 for 24 h, and subsequently transfected with P301L-V5 for another 24 h. Cells were then treated with 0.1 or 1 mM
of 17AAG for 24 h, and cell lysates immunoblotted for PHF1-tau, HDAC6, Hsp70 and GAPDH to control for protein loading. (B) Analysis of PHF1-tau levels by
two-way ANOVA veriﬁed a signiﬁcant treatment effect of 17AAG (F ¼ 21.1, P ¼ 0.0001) and siHDAC6 (F ¼ 24.5, P ¼ 0.0003), as well as a signiﬁcant inter-
action between 17AAG and siHDAC6 (F ¼ 5.75, P ¼ 0.02). (C) HeLa cells were transfected to overexpress P301L-V5 for 24 h, pretreated with the HDAC6
inhibitor M344 for 1 h and subsequently treated with 0.1–1 mM 17-AAG for an additional 24 h. Levels of PHF1-tau and Hsp70 present in cell lysates were
examined by immunoblotting. (D) Analysis of PHF1-tau levels by two-way ANOVA conﬁrmed a signiﬁcant treatment effect of both 17AAG (F ¼ 33.73,
P , 0.0001) and M344 (F ¼ 153.3, P , 0.0001). All data are presented as mean+SEM (n ¼ 3). (E) HeLa cells were transfected to overexpress P301L-V5
for 24 h, pretreated with 1 mM MG132 for 1 h and subsequently treated with 1 mM M344 and CHX for 4, 8 or 12 h to inhibit the continued translation of
tau. Levels of PHF1-tau and GAPDH present in cell lysates were examined by immunoblotting. (F) The rate of degradation of PHF1-tau post-CHX treatment
in vehicle, M344 or MG132 + M344-treated cells was compared by normalizing values at each time point to their respective levels at 0 h CHX treatment. There
was a signiﬁcant difference in the rate of degradation between vehicle, M344 and MG132 + M344-treated samples as assessed by two-way ANOVA (effect of
M344 or MG132 + M344 treatment F ¼ 6.4; P ¼ 0.01; effect of CHX treatment F ¼ 95.3; P , 0.0001; interaction F ¼ 3.4; P ¼ 0.04). Estimated half-life was
the following: vehicle, 5 h; M344, 3.8 h; MG132 + M344, 6.4 h). Data from this experiment are presented as mean+SEM (n ¼ 2). ∗∗P , 0.001, ∗P , 0.05.
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CHIP is intimately involved in the mechanisms of
Hsp-mediated client degradation, and seems to be an integral
participant in the removal of hyperphosphorylated tau. It has
a unique binding afﬁnity for tau phosphorylated at disease-
speciﬁc phospho-epitopes, and is required for the ubiquitina-
tion of these tau species, leading to their proteasome-mediated
degradation (6–8). In addition to directly promoting tau
clearance by ubiquitination, CHIP may also facilitate tau deg-
radation by abrogating the protein folding function of Hsp90.
Indeed, CHIP has been shown to elicit the release of p23 from
Hsp90 upon binding (32), thereby causing a shift in the func-
tion of Hsp90 from refolding client proteins to promoting their
degradation. We have now identiﬁed an additional, novel
mechanism by which CHIP regulates protein triage decisions
involving Hsp90. Speciﬁcally, our data suggest that CHIP
facilitates tau clearance by decreasing the steady-state levels
Figure 5. HDAC6 knockdown and inhibition decrease cochaperone p23 levels. (A) HeLa cells were transfected with siCON or siHDAC6 for 48 h, and then
treated with vehicle (DMSO) or 1 mM of 17-AAG for an additional 24 h. Cell lysates were immunoblotted for p23 and GAPDH, the latter as a control for
protein loading. (B) Levels of p23 were quantiﬁed and normalized to GAPDH, and analysis by two-way ANOVA revealed a signiﬁcant effect of siHDAC6
on p23 (F ¼ 82.02; P , 0.0001), as well as a signiﬁcant treatment effect of 17AAG (F ¼ 47.07; P ¼ 0.0001), but no interaction between siHDAC6 and
17AAG (F ¼ 0.25; P ¼ 0.63). (C) HeLa cells were pretreated with the HDAC6 inhibitor M344 for 1 h, and subsequently treated with vehicle (DMSO) or
1 mM 17AAG for an additional 24 h. Levels of p23 and GAPDH in cell lysates were examined by immunoblotting. (D) Levels of p23 were quantiﬁed and normal-
ized to GAPDH, and analysis by two-way ANOVA revealed a signiﬁcant effect of M344 leading to a decrease in p23 (F ¼ 52.6; P , 0.0001), as well as a
signiﬁcant treatment effect of 17AAG (F ¼ 9.6; P ¼ 0.01). All data are presented as mean+SEM (n ¼ 3). ∗∗P , 0.001, ∗P , 0.01.
Figure 6. HDAC6 inhibition decreases tau levels in primary neuronal cultures. (A) Primary neurons from non-transgenic mice (129SVE × FVB) were cultured
for 9 days, treated with vehicle (50% ethanol) or M344 (1 mM) for 24 h and harvested on the 10th day in vitro (DIV). Cell lysates were immunoblotted for
PHF1-tau, acetylated tubulin, p23, and total tubulin. (B) Treatment with 1 mM M344 for 24 h led to a signiﬁcant decrease in PHF1-tau levels in primary
neurons (t ¼ 4.7; P ¼ 0.01). (C) Assessment of acetylated-tubulin levels veriﬁed that M344 does inhibit the deacetylase activity of HDAC6 and promotes
increased acetylation of tubulin (t ¼ 29.7; P , 0.0001). (D) Levels of p23 were also quantiﬁed and normalized to tubulin, and statistical analysis revealed a
signiﬁcant effect of M344 leading to a decrease in p23 (t ¼ 13.74; P ¼ 0.0002). (E) On DIV9, primary neurons were treated with vehicle (50% ethanol) or
M344 (1 mM) for 1 h, and subsequently treated with vehicle (DMSO) or the indicated concentration of 17AAG for an additional 23 h. Cell lysates were immuno-
blotted for Hsp70, acetylated tubulin and total tubulin. (F) HSPA1A mRNA expression was evaluated in primary neuronal cultures pretreated with vehicle (50%
ethanol) or M344 (1 mM) for 1 h and subsequently treated with vehicle (DMSO) or 17AAG (1 mM) for an additional 23 h. GAPDH was used as an endogenous
loading control for each sample (n ¼ 3 per condition), and each sample was analyzed in quadruplicate. Results were analyzed by two-way ANOVA, revealing a
signiﬁcant effect of 17AAG (F ¼ 62.31; P , 0.0001), as well as a signiﬁcant effect of M344 (F ¼ 29.82; P , 0.0001) on Hsp70 mRNA levels. All data are
presented as mean+SEM (n ¼ 3). ∗∗P ≤ 0.0002, ∗P ¼ 0.01.
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17-AAG through acetylation and promoting client degradation
(Fig. 7).
In this report, we present evidence demonstrating that CHIP
interacts with and ubiquitinates HDAC6 (Fig. 1). HDAC6
likely undergoes CHIP-mediated proteasomal degradation,
given that knocking-down CHIP in cultured cells and
knocking-out CHIP in mice both result in elevated HDAC6
levels (Fig. 2). Increases in HDAC6, in turn, have detrimental
consequences on tau levels. Indeed, we show that HDAC6
overexpression promotes the accumulation of tau (Fig. 3);
conversely, HDAC6 deﬁciency decreases tau (Figs 4 and 6).
We propose that changes in HDAC6 indirectly inﬂuence
whether or not tau is degraded by modulating the acetylation
state of Hsp90. As mentioned, Hsp90 hyperacetylation pro-
motes client degradation (18,21). Since Hsp90 is a substrate
for the deacetylase activity of HDAC6, loss of HDAC6 ex-
pression would promote Hsp90 acetylation, thereby favoring
tau degradation. In contrast, an increase in HDAC6 would de-
crease Hsp90 acetylation, and therefore cause a decrease in tau
degradation. Given that HDAC6 can form an Hsp90/HDAC6/
HSF1 complex (33,34), it is possible that alterations in
HDAC6 expression disrupt Hsp90 chaperone function due to
changes in complex formation, and not due to HDAC6-
mediated deacetylation of Hsp90. However, because the cata-
lytically inactive HDAC6 mutant (H216A/H611A) fails to
promote tau accumulation (Fig. 3D), it is most likely that
HDAC6-mediated tau accumulation is dependent on the dea-
cetylase function of HDAC6.
Not only do HDAC6 depletion and inhibition enhance tau
clearance, they also augment Hsp90 inhibitor-mediated tau
degradation (Figs 4 and 6). This is consistent with ﬁndings
that hyperacetylation of Hsp90 due to HDAC6 depletion
leads to an increased binding afﬁnity of Hsp90 for Hsp90 inhi-
bitors (21,22). Indeed, we show that Hsp70 induction, a conse-
quence of effective Hsp90 inhibition by 17AAG, is enhanced
in primary neurons treated with the HDAC6 inhibitor, M344
(Fig. 6E). That a similar increase in 17AAG-mediated induc-
tion of Hsp70 following HDAC6 inhibition in HeLa cells
was not observed (Fig. 4) is most likely due to the difference
in basal levels of inducible Hsp70 between HeLa cells (in
which it is high) and primary neurons (in which it is low).
Currently, modulation of the Hsp90 chaperone complex
with chemical inhibitors to promote the degradation of
Hsp90 client proteins is being tested in clinical trials as a
therapeutic approach for the treatment of cancer (reviewed
in 35). In cancer, cell death pathways are often blocked by
the overexpression of prosurvival Hsp90 client proteins that
promote uncontrolled cell proliferation (16,36,37). Hsp90 in-
hibition results in the ubiquitination and proteasomal degrad-
ation of these deleterious client proteins. It is noteworthy
that Hsp90 chaperone complexes from tumor cells exhibit a
high afﬁnity for Hsp90 inhibitors when compared with
Hsp90 chaperone complexes from normal cells (38,39), dem-
onstrating that treatment with Hsp90 inhibitors can be used to
selectively target diseased cells. These ﬁndings form the basis
for the use of Hsp90 inhibitors in the treatment of cancer. Of
importance, there is a signiﬁcant amount of evidence indicat-
ing that Hsp90 inhibitors may also hold clinical relevance for
the treatment of neurodegenerative diseases characterized by
abnormal tau accumulation. For instance, the increase in phos-
phorylated tau associated with disease, as well as the ability of
Hsp90 inhibition to promote the preferential degradation of
phosphorylated tau species in pathogenic models, conclusively
identiﬁes tau as an Hsp90 client protein, and further implicates
Hsp90 dysfunction in the pathogenesis of disease (9,14,27,28).
Moreover, the demonstration that the Hsp90 chaperone
complex exhibits a high binding afﬁnity for Hsp90 inhibitors
only in affected brain regions of AD patients, and not in un-
affected regions (9), suggests that similarly to cancer, Hsp90
inhibitors can be used to selectively target Hsp90 chaperone
complexes in diseased areas of the brain. Certainly, with the
potential clinical applications of Hsp90 inhibitors for tauopa-
thies, deciphering the mechanisms that cause Hsp90 to adopt
a high afﬁnity state for Hsp90 inhibitors is of considerable
interest. Hsp90 has a higher binding afﬁnity for Hsp90 inhibi-
tors when acetylated (21,22), and we hypothesize that CHIP
modulates the afﬁnity of Hsp90 for Hsp90 inhibitors by regu-
lating levels of the deacetylase, HDAC6. In addition to ubiqui-
tinating clients for targeting to the proteasome (6–8), CHIP
may regulate protein triage decisions by modulating the
folding and degradation functions of Hsp90 via HDAC6.
Given that a treatment paradigm combining HDAC6 and
Hsp90 inhibition has been shown to synergistically and select-
ively augment Hsp90 client degradation in leukemia cells but
not normal cells (21), it is possible that a similar approach
could be utilized in neurodegenerative disease to selectively
target Hsp90 chaperone complexes present in cells expressing
pathological client proteins, such as phosphorylated tau. While
exploring the therapeutic beneﬁt of modulating HDAC6 func-
tion, the relationship among tau pathology, HDAC6 activity
and Hsp90 acetylation should be more fully characterized. It
has been demonstrated that tau overexpression inhibits
HDAC6 in a cell culture model (40). Additionally, the overex-
pression of tau leads to an increase in tubulin acetylation (41),
which is indicative of a loss of HDAC6 function. By inhibiting
HDAC6, tau may indirectly regulate the acetylation of Hsp90.
Given that increased acetylation of Hsp90 increases the
binding afﬁnity of the Hsp90 chaperone complex for Hsp90
inhibitors, it is possible that the increased binding afﬁnity of
the Hsp90 chaperone complex observed in affected regions
of AD brain (9) could be due to hyperacetylation of Hsp90
Figure 7. CHIP and HDAC6 levels modulate Hsp90 chaperone complex.
Schematic diagram depicting how CHIP and HDAC6 levels inﬂuence forma-
tion of an Hsp90 chaperone complex either favoring refolding or degradation
of client proteins, and the resulting impact on tau accumulation. Speciﬁcally,
decreased HDAC6 activity favors formation of a ‘degradation’ complex,
driving tau clearance. Conversely, upregulation of HDAC6 or loss of CHIP
promotes formation of a ‘refolding’ complex, which leads to tau accumulation.
2942 Human Molecular Genetics, 2012, Vol. 21, No. 13as a result of pathological tau-mediated inhibition of HDAC6.
However, the level of Hsp90 acetylation in affected areas of
the AD brain remains to be determined. Regardless, given
the importance of protein quality control in neurodegenerative
diseases, the current ﬁndings will not only beneﬁt the tau ﬁeld,
but are also expected to have broad implications for all dis-
eases characterized by the accumulation and aggregation of
abnormal Hsp90 client proteins.
MATERIALS AND METHODS
Antibodies, chemicals and reagents
PHF1 (1:500; anti-S396/S404 p-tau) was provided by
P. Davies (Albert Einstein College of Medicine, New York,
NY, USA). Anti-myc (1:1000) and anti-HA (1:1000) were
obtained from Roche Applied Science. Anti-HDAC6
(1:1000) was purchased from Millipore. Anti-GFP (1:2000)
and anti-V5 (1:1000) were obtained from Life Technologies.
Anti-actin (1:10000) was obtained from Sigma Aldrich.
Anti-hsp70 (1:1000) was obtained from Enzo Life Sciences.
Anti-GAPDH (1:10 000) was obtained from Meridian Life
Science, Inc. Anti-p23 (1:1000) was obtained from Fisher Sci-
entiﬁc. Anti-CHIP (1:1000) and E1 (1:1000; human speciﬁc
tau antibody) were generated by our group. 17AAG was pur-
chased from A.G. Scientiﬁc, M344 and cycloheximide were
obtained from Sigma-Aldrich and MG132 was purchased
from Cayman Chemical.
All siRNAs were obtained from Qiagen, with the propri-
etary sequence of the non-silencing control not disclosed by
the company. The target sequence for siCHIP (STUB1) is
TGCCGCCACTATCTGTGTAAT, and the target sequence
for siHDAC6 is CACCGTCAACGTGGCATGGAA. siRNA
efﬁciencyforproteinknockdownwasvalidatedbywesternblot.
Expression plasmids
GFP, untagged and myc-tagged CHIP, P301L-V5 tau and
HA-ubiquitin were generated by our lab. A human HDAC6
clone in a pCMV SPORT6 vector was purchased from Life
Technologies. The QuikChange Mutagenesis kit (Stratagene)
was utilized to generate a catalytically inactive HDAC6
mutant (H216A/H611A) following the manufacturer’s proto-
col. The QuikChange Mutagenesis kit was also utilized to gen-
erate K30A and H260Q mutations in myc-CHIP. The integrity
of all constructs was conﬁrmed by automated sequencing.
Cell culture and transient transfections
HeLa and HEK-293T were maintained in Opti-Mem (Life
Technologies) supplemented with 10% heat-inactivated FBS
(Life Technologies) and passaged every 3–4 days based on
90% conﬂuency.
siRNA experiments were carried out in six-well plates using
human gene-speciﬁc validated and genome-wide siRNAs.
Final siRNA concentration per well was 20 nM in Opti-Mem,
with 4 ml of siLentFect transfection reagent (Bio-Rad) used
per well. This mixture was incubated in a ﬁnal volume of
500 ml for 20 min and then added to 40–50% conﬂuent
HeLa cells in six-well plates for a ﬁnal in-well volume of
2 ml. Forty-eight hours after transfection, the complete
medium was removed and replaced with serum-free
Opti-Mem for subsequent plasmid transfection.
For plasmid transfections, 1–2 mg plasmid DNA was com-
bined with Lipofectamine 2000 reagent for 15 min in 500 ml
Opti-Mem, and this mixture was added to either untreated or
siRNA-transfected cells for 4 h. The transfection mixture
was then replaced with fresh complete media.
Immunoprecipitation
For coimmunoprecipitation studies, 90% of conﬂuent cells in
10 cm dishes were transfected using Lipofectamine 2000 with
the combinations of HA-ubiquitin, HDAC6, myc-HDAC6,
GFP, CHIP and myc-CHIP (WT, K30A and H260Q mutants)
for 4 h and then maintained in complete media for 48 h. Cells
were collected in coimmunoprecipitation buffer (50 mM Tris,
274 mM NaCl, 5 mM KCl, 5 mM EDTA, 1% Triton X-100,
1m M PMSF and a protease and phosphatase inhibitor cocktail),
supernatants were precleared with protein G and subsequently
incubated with anti-myc antibody or anti-HDAC6 antibody
and 20 ml protein G overnight at 48C. Protein G beads were
washed three times in coimmunoprecipitation buffer, resus-
pended in 2× tris-glycine SDS sample buffer with 5% beta-
mercaptoethanol, heated for 5 min at 958C and subjected to
western blot analyses following SDS–PAGE electrophoresis.
Mice
CHIP
–/– mice were generated as previously described (42).
CHIP
–/– and CHIP
+/+ mice were humanely euthanized at
30 days of age, and their brains were quickly removed for dis-
section and frozen on dry ice for subsequent biochemical ana-
lyses. Brain tissue was homogenized in buffer containing
50 mM Tris, 274 mM NaCl, 5 mM KCl, 5 mM EDTA, 1%
SDS, 1% Triton X-100, 1 mM PMSF and a protease and phos-
phatase inhibitor cocktail (pH 7.4). Homogenates were centri-
fuged at 15400g for 15 min, and supernatants were collected
and subjected to western blot analyses.
Sample preparation and immunoblotting procedure
Cell samples for immunoblotting were suspended in 100–
200 ml of homogenate buffer [50 mM Tris–HCl, pH 7.4,
300 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% SDS,
1m M PMSF, protease inhibitor cocktail, phosphatase inhibi-
tors I and II (Fisher Scientiﬁc)]. Mice brains were weighed
and homogenized in 10× volume of homogenate buffer. All
samples were sonicated, and following sonication, samples
were centrifuged at 16 000g for 15 min, and a BCA protein
assay (Fisher Scientiﬁc) performed on the supernatant.
Thirty microgram of protein from each sample was diluted
in dH2O, 2× tris-glycine SDS sample buffer (Life Technolo-
gies), 5% beta-mercaptoethanol (Sigma Aldrich) and heat-
denatured for 5 min at 958C. Samples were run on 4–20% tris-
glycine gels (Life Technologies), and transferred to PVDF
membrane (Millipore). Membranes were blocked in 5% milk
in TBS/0.1% Triton X-100, and incubated overnight in
primary antibody diluted in 5% milk in TBS/0.1% Triton
X-100 rocking at 48C. Membranes were incubated in
Human Molecular Genetics, 2012, Vol. 21, No. 13 2943HRP-conjugated secondary antibodies (1:5000; Jackson
Immuno) for 1 h at room temperature, and detected by ECL
(PerkinElmer).
Primary neuronal culture
For primary neuronal cultures, hippocampi from postnatal day
2 mouse pups were removed and stored at 48Ci n
HIBERNATETM A media without calcium (BrainBits), sup-
plemented with B27 (Life Technologies), 0.5 mM GMAX
(Life Technologies) and gentamicin (Life Technologies).
Excised hippocampi were digested in papain (1 mg/ml;
Fisher Scientiﬁc), triturated with a Pasteur pipet (bore size
0.8–1 mM), centrifuged to collect cell pellet, and resuspended
in Neurobasal A (Life Technologies), supplemented with B27,
GMAX, gentamicin and bFGF (Life Technologies). Following
determination of cell number, neurons were plated on
poly-D-lysine-coated cover slips within 24-well plates for im-
munocytochemical studies (seeded at a density of 2.5 × 10
4
cells/cover slip), or seeded at a density of 3 × 10
5 cells/well
on poly-D-lysine-coated six-well plates for immunoblotting.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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